• S1 Episode 1: High-Impact Type 2 Diabetes Treatment Guidelines
    Mar 22 2022

    Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. Get the upshot on best evidence from leading experts Drs Silvio Inzucchi and Rita Kalyani.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963267). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment

    Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes https://www.fda.gov/media/71297/download

    Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1603827

    Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042007

    Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext

    Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa1607141

    SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis of the EMPEROR-Reduced and DAPA-HF Trials https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext

    The SGLT2 Inhibitor Dapagliflozin in Heart Failure With Preserved Ejection Fraction: A Multicenter Randomized Trial https://www.nature.com/articles/s41591-021-01536-x

    A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL) https://clinicaltrials.gov/ct2/show/NCT04865770

    Show more Show less
    24 mins
  • S1 Episode 2: A Brave New World in Type 2 Diabetes Treatment and Beyond
    Mar 22 2022

    Where are the biggest cardiovascular benefits for your patients with type 2 diabetes? Host Dr Silvio Inzucchi and cardiologist Dr Mikhail Kosiborod reveal winning strategies — for managing much more than just type 2 diabetes.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963270). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    New ACC Guidance on CVD Risk Reduction in Diabetes https://www.medscape.com/viewarticle/935218

    Type 2 Diabetes in Adults: Management https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#blood-glucose-management

    Type 2 Diabetes and Causes of Sudden Cardiac Death: A Systematic Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525691/

    Cardiometabolic Medicine – the US Perspective on a New Subspecialty https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410029/pdf/xce-9-070.pdf

    Antidiabetics, Glucagon-like Peptide-1 Agonists https://reference.medscape.com/drugs/antidiabetics-glucagon-like-peptide-1-agonists

    Antidiabetics, SGLT2 Inhibitors https://reference.medscape.com/drugs/antidiabetics-sglt2-inhibitors

    Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/31189511/

    Mechanistic Insights Regarding the Role of SGLT2 Inhibitors and GLP1 Agonist Drugs on Cardiovascular Disease in Diabetes https://pubmed.ncbi.nlm.nih.gov/31381891/

    SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-analysis of Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/30424892/

    Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial https://pubmed.ncbi.nlm.nih.gov/33736819/

    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1812389

    CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis https://diabetesjournals.org/care/article/39/7/1108/37341/CV-Protection-in-the-EMPA-REG-OUTCOME-Trial-A

    Worldwide Inertia to the Use of Cardiorenal Protective Glucose-Lowering Drugs (SGLT2i and GLP-1 RA) in High-Risk Patients with Type 2 Diabetes https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01154-w

    Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/30291013/

    High-Sensitivity C-Reactive Protein https://emedicine.medscape.com/article/2094831-overview#:~:text=hs%2DCRP%20is%20an%20important,predicts%20mortality%20and%20cardiac%20complications.

    Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know https://www.medscape.com/viewarticle/960356

    Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34215025/

    Coronary Artery Calcification on CT Scanning https://emedicine.medscape.com/article/352189-overview

    Show more Show less
    21 mins
  • S1 Episode 3: How to Reduce Renal Risk in Type 2 Diabetes
    Apr 13 2022

    Want to prevent kidney disease progression in patients with type 2 diabetes? Join host Dr Silvio Inzucchi and nephrologist Dr David Cherney as they unpack the how and why behind current recommendations.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963275). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf

    Introduction: ADA Standards of Medical Care https://diabetesjournals.org/care/issue/45/Supplement_1

    Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes — 2022 https://diabetesjournals.org/care/article/45/Supplement_1/S39/138909/3-Prevention-or-Delay-of-Type-2-Diabetes-and

    Show more Show less
    25 mins
  • S1 Episode 4: Better Ways to Sustain Weight Loss in Type 2 Diabetes
    May 18 2022

    Patients with type 2 diabetes and obesity have more options today than ever before. Join host Dr Silvio Inzucchi and obesity expert Dr Ania Jastreboff as they discuss how to successfully support weight loss in people with type 2 diabetes.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963276). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Long-term Drug Treatment for Obesity: A Systematic and Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928674/

    What's New in Medications for Weight Management for People With Diabetes https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/new-in-medications-for-weight-management

    FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014

    Diabetes and Obesity -- Inextricable Diseases https://www.heraldopenaccess.us/openaccess/diabetes-and-obesity-inextricable-diseases

    Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline https://academic.oup.com/jcem/article/100/2/342/2813109

    Show more Show less
    24 mins
  • S1 Episode 5: Type 2 Diabetes Care Equity: What Can You Do?
    Jun 15 2022

    Are health equity and better outcomes within reach for all patients with type 2 diabetes? Drs Enrique Caballero and Silvio Inzucchi discuss how we can change the status quo.

    Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963277). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    National Health and Nutrition Examination Survey https://www.cdc.gov/nchs/about/factsheets/factsheet_nhanes.htm

    Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016 https://jamanetwork.com/journals/jama/fullarticle/2757817

    Diabetes mellitus in the Pima Indians: Genetic and evolutionary considerations https://pubmed.ncbi.nlm.nih.gov/6624895/

    HbA1c Performance in African Descent Populations in the United States With Normal Glucose Tolerance, Prediabetes, or Diabetes: A Scoping Review https://www.cdc.gov/pcd/issues/2021/20_0365.htm

    Show more Show less
    21 mins
  • S1 Episode 6: Future Type 2 Diabetes Drugs: Exciting and a Little Scary
    Jul 12 2022

    Who are the likely beneficiaries of more nuanced diabetes treatments, and how might these agents advance diabetes care? Silvio Inzucchi, MD, and guest Joshua Neumiller, PharmD, dig deep into recent drug developments.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963278). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment

    Patient Education Interventions Improve A1C Values https://pubmed.ncbi.nlm.nih.gov/35426637/

    Therapeutics for Type-2 Diabetes Mellitus: A Glance at the Recent Inclusions and Novel Agents Under Development for Use in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474306/

    Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S39/138909/3-Prevention-or-Delay-of-Type-2-Diabetes-and

    Show more Show less
    22 mins
  • S2 Episode 1: How to Care for Older Adults With Type 2 Diabetes
    Feb 1 2023

    Drs Carol Wysham and Medha N. Munshi discuss the unique challenges and strategies when treating older adults with type 2 diabetes.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982414). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview

    Diabetes in Older Adults: A Consensus Report https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.12035

    Geriatrics https://www.medscape.com/resource/geriatric

    Hypoglycemia https://emedicine.medscape.com/article/122122-overview

    Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline https://academic.oup.com/jcem/article/104/5/1520/5413486

    Sodium-Glucose Cotransporter 2 Inhibitors: An Overview https://www.medscape.com/viewarticle/892957_9

    Euglycemic Diabetic Ketoacidosis https://www.ncbi.nlm.nih.gov/books/NBK554570/

    Show more Show less
    20 mins
  • S2 Episode 2: Recognizing the Signs: Heart Failure and Type 2 Diabetes
    Feb 1 2023

    Join Dr Carol Wysham and Dr Javed Butler as they discuss the stealth complication of heart failure in patients with type 2 diabetes, including subtle signs and symptoms of heart failure and the importance of early detection and treatment.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982415). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720

    Framingham Heart Study https://www.framinghamheartstudy.org/

    Heart Failure https://emedicine.medscape.com/article/163062-overview

    Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association https://diabetesjournals.org/care/article/45/7/1670/147048/Heart-Failure-An-Underappreciated-Complication-of

    Brain-Type Natriuretic Peptide (BNP) https://emedicine.medscape.com/article/2087425-overview

    The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure https://www.nejm.org/doi/full/10.1056/NEJM199909023411001

    Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms https://www.nejm.org/doi/full/10.1056/nejmoa1009492

    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063

    Show more Show less
    23 mins